Novogratz' Galaxy Digital opens trading on the Nasdaq at $23.50 per share
Mike Novogratz' crypto firm Galaxy Digital started trading on the Nasdaq Friday under the ticker GLXY. The stock opened at $23.50 per share on the U.S. exchange.
Galaxy Digital, which has been traded on the Toronto Stock Exchange since 2020, shifted its shares to the Nasdaq through a direct listing — a move that follows a grueling, multi-year battle with U.S. regulators.
Novogratz told CNBC's "Squawk Box" Friday that Galaxy's value now hinges on two high-growth areas: crypto and artificial intelligence.
"These are the two most exciting growth areas in markets, right. AI and the infrastructure needed for AI to exist and crypto finally ... at the brink of institutional adoption," he said. "We have built our company for this moment, so I couldn't be more excited."
This self-driving car technology stock could pop by more than 400%, say three analysts
Looking for alternatives to Nvidia? Futurum CEO names 3 he's bullish on for 2024
Bernstein tech analyst's best idea for 2024 is to short Tesla
Morgan Stanley picks 'alpha' opportunities in China tech - giving one 52% upside
Novogratz said Galaxy is effectively two businesses now: "We are a data center company and a crypto company."
The Nasdaq listing comes after four years of regulatory delays, with Galaxy spending more than $25 million and enduring nine rounds of back-and-forth comments with the U.S. Securities and Exchange Commission, according to Novogratz. What should have taken at most, 90 days, stretched to 1,320, he said.
"You needed to be very well capitalized — and a pretty big, strong company — just to stay in the game," Novogratz told CNBC.
The billionaire also pointed to the U.S. market's unmatched depth, saying Galaxy's visibility in Canada was one-thirtieth of what it could achieve in the United States.
"If we had been in the U.S. markets those four years, we'd be a different company," he said.
The listing follows eToro's successful Nasdaq debut this week, signaling renewed investor appetite for crypto-adjacent firms after years of regulatory caution.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
23 minutes ago
- Business Upturn
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative in vivo gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14th 6:30 – 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy. In this study, the Company's proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the HBG1/2 promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs. 'These data from our in vivo HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,' said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the HBG1/2 promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials. The presentation details are listed below. Abstracts can be accessed on the EHA website , and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for β-hemoglobinopathies Date/Time: Saturday, June 14, 2025, 6:30 – 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit . Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
30 minutes ago
- Yahoo
Vera Bradley Inc (VRA) Q1 2026 Earnings Call Highlights: Navigating Leadership Changes and ...
Release Date: June 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Vera Bradley Inc (NASDAQ:VRA) is undergoing a leadership transition with a focus on accelerating transformation and improving results. The company has formed a new Strategy and Transformation Committee to refine strategic direction and growth initiatives. Vera Bradley Inc (NASDAQ:VRA) has successfully diversified its wholesale accounts, including new partnerships with Costco and Urban Outfitters Marketplace. The company has seen a notable performance on the Target Marketplace, leading to further discussions to maximize the partnership. Recently acquired new customers now comprise 45% of the active 12-month file, showing a shift in customer demographics and product affinities. Vera Bradley Inc (NASDAQ:VRA) reported a decrease in consolidated revenues to $51.7 million from $67.9 million in the prior year first quarter. The company experienced a 23.6% decrease in the Vera Bradley Direct segment revenues due to traffic and conversion declines. Gross margins declined due to channel shifts from stores to online sites, contributing to increased outbound freight costs. The company reported a non-GAAP net loss from continuing operations of $10 million, compared to a $6.6 million loss in the prior year. Vera Bradley Inc (NASDAQ:VRA) has suspended its prior year guidance due to leadership changes and uncertainty in the consumer environment. Warning! GuruFocus has detected 4 Warning Signs with VRA. Q: Can you provide more details on the leadership transition and the search for a new CEO? A: Ian Bickley, the incoming Executive Chairman, explained that Jackie will be departing at the end of July, and the Board has initiated a nationwide search for a new CEO. Ian will serve as Executive Chairman during the transition to ensure steady leadership until a new CEO is appointed. Q: How is Vera Bradley addressing the shift in customer demographics and preferences? A: Jacqueline Ardrey, CEO, noted that the company is focusing on restoring and modernizing the brand through product, brand, customer, and channel strategies. They are increasing the penetration of classic Vera Bradley products and have introduced new collections and partnerships to appeal to both new and existing customers. Q: What were the key financial results for the first quarter of fiscal 2026? A: Michael Schwindle, CFO, reported that consolidated revenues were $51.7 million, a decrease from the previous year. The net loss from continuing operations was $10 million. The Direct segment saw a 23.6% revenue decline, while the Indirect segment decreased by 25.6%. Q: How is Vera Bradley managing inventory and cost efficiencies? A: Michael Schwindle highlighted that inventory decreased by 3% year-over-year due to changes in merchandising processes. The company is focused on redefining inventory acquisition and management to improve product flow and quality, which has already shown positive impacts. Q: What is the company's outlook and guidance for the future? A: Due to leadership changes and consumer environment uncertainties, Vera Bradley has suspended its prior guidance and is not providing forward guidance at this time. The focus remains on business transformation and improving performance. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
MIND Technology Inc (MIND) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Revenue: $7.9 million for the first quarter of fiscal 2026, down approximately 18% from the same period a year ago. Gross Profit: $3.3 million, with a gross profit margin of 42% for the quarter. General and Administrative Expenses: Approximately $3.4 million for the first quarter. Research and Development Expense: $380,000 for the first quarter. Operating Loss: Approximately $658,000 for the first quarter. Adjusted EBITDA: Loss of approximately $179,000 for the first quarter. Net Loss: Approximately $970,000 for the first quarter. Cash Flow from Operations: Approximately $4.1 million, an improvement of approximately 98% sequentially. Backlog of Firm Orders: Approximately $21 million as of April 30, 2025. Cash on Hand: $9.2 million as of April 30, 2025. Warning! GuruFocus has detected 5 Warning Signs with MIND. Release Date: June 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MIND Technology Inc (NASDAQ:MIND) reported a strong cash flow from operations of $4.1 million, indicating improved liquidity. The company has a solid backlog of firm orders amounting to approximately $21 million as of April 30, 2025, up from $16.2 million at the end of January 2025. MIND Technology Inc (NASDAQ:MIND) is strategically positioned for growth with a resilient business model, improved order visibility, and a strong demand environment. The company is expanding its facility in Huntsville, Texas, which is expected to contribute significantly to revenue through additional repair and manufacturing services. MIND Technology Inc (NASDAQ:MIND) maintains a clean, debt-free balance sheet with a simplified capital structure, enhancing financial flexibility and shareholder value. The first-quarter results were down sequentially due to a $5.5 million delay in order deliveries, impacting revenue and profit margins. General and administrative expenses increased to $3.4 million, partly due to nonrecurring costs related to restructuring and tax analysis. The company reported an operating loss of approximately $658,000 and a net loss of $970,000 for the first quarter. Adjusted EBITDA was a loss of approximately $179,000, impacted by nonrecurring expenses. MIND Technology Inc (NASDAQ:MIND) faces challenges in utilizing its $80 million in US tax loss carryforwards due to the majority of its revenue being generated outside the United States. Q: On the $5.5 million delayed delivery, have those been delivered yet? And are they mainly comprised of one or two systems? A: Partially delivered. There was one large system and a few other orders. So it's a little bit of both. It will be soon, though. - Robert Capps, President, Chief Executive Officer, Director Q: On the tax loss carryforwards, what did you determine as the amount that you reasonably have that could be used in the future? A: It's about USD 80 million of NOL carryforward roughly. - Robert Capps, President, Chief Executive Officer, Director Q: Are you seeing increased interest in your technology from industries like deep-sea mining and rare earth elements? A: Yes, existing and potential new customers are looking to use their expertise in exploration survey work, which aligns with our SeaLink product line. - Robert Capps, President, Chief Executive Officer, Director Q: Do you have any active master supply agreements with larger customers, and is this approach favorable for Mind? A: We have such agreements with some larger customers, which facilitate new business by providing a framework for general terms and conditions. - Robert Capps, President, Chief Executive Officer, Director Q: Can you provide more details on the new streamer system and customer interest? A: It's more of an enhancement of what we have, allowing us to address additional markets. I prefer not to get too detailed for competitive reasons. - Robert Capps, President, Chief Executive Officer, Director Q: How did the $5.5 million delay impact your earnings in the quarter? A: It would have added about $2 million of operating profit or gross profit, roughly $0.25 a share at the gross profit level. - Robert Capps, President, Chief Executive Officer, Director Q: How much have you invested in the Texas repair facility, and how will it impact your financials? A: We've spent roughly $0.5 million. It should generate several million dollars a year of additional revenue, helping utilize tax losses. - Robert Capps, President, Chief Executive Officer, Director Q: Can you provide more information about your arrangement with the German company [GWL]? A: It's a partnership to bring a new product concept to market, and we'll have more to say about it in the near future. - Robert Capps, President, Chief Executive Officer, Director For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
